TY  - JOUR
AU  - Hammes, Jochen
AU  - Bischof, Gérard N.
AU  - Bohn, Karl P.
AU  - Onur, Özgür
AU  - Schneider, Anja
AU  - Fliessbach, Klaus
AU  - Hönig, Merle C
AU  - Jessen, Frank
AU  - Neumaier, Bernd
AU  - Drzezga, Alexander
AU  - van Eimeren, Thilo
TI  - One-Stop Shop: 18 F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases
JO  - Journal of nuclear medicine
VL  - 62
IS  - 2
SN  - 2159-662X
CY  - New York, NY
PB  - Soc.
M1  - FZJ-2021-02079
SP  - 240 - 246
PY  - 2021
AB  - Tau protein aggregations are a hallmark of amyloid-associated Alzheimer disease and some forms of non–amyloid-associated frontotemporal lobar degeneration. In recent years, several tracers for in vivo tau imaging have been under evaluation. This study investigated the ability of 18F-flortaucipir PET not only to assess tau positivity but also to differentiate between amyloid-positive and -negative forms of neurodegeneration on the basis of different 18F-flortaucipir PET signatures. Methods: The 18F-flortaucipir PET data of 35 patients with amyloid-positive neurodegeneration, 19 patients with amyloid-negative neurodegeneration, and 17 healthy controls were included in a data-driven scaled subprofile model (SSM)/principal-component analysis (PCA) identifying spatial covariance patterns. SSM/PCA pattern expression strengths were tested for their ability to predict amyloid status in a receiver-operating-characteristic analysis and validated with a leave-one-out approach. Results: Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83. A support vector machine classification based on pattern expression strengths in 2 different SSM/PCA components yielded a prediction accuracy of 98%. Anatomically, prediction performance was driven by parietooccipital gray matter in amyloid-positive patients versus predominant white matter binding in amyloid-negative patients. Conclusion: SSM/PCA-derived binding patterns of 18F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition (18F-FDG PET–equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).
LB  - PUB:(DE-HGF)16
C6  - 32620704
UR  - <Go to ISI:>//WOS:000621322300018
DO  - DOI:10.2967/jnumed.120.244061
UR  - https://juser.fz-juelich.de/record/892433
ER  -